Company news
Pharvaris N.V. news in 2021
Pharvaris N.V.'s news releases, calls and decks from 2021, newest first.
Pharvaris Announces Changes to its Board of Directors
December 21, 2021
Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights
November 9, 2021
Pharvaris to Participate in Upcoming September Investor Conferences
September 2, 2021
Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights
July 29, 2021
Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
July 9, 2021
Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
June 30, 2021
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop
June 3, 2021
Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights
May 25, 2021
Pharvaris Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer
May 11, 2021
Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
April 28, 2021
Pharvaris Announces FDA Acceptance of IND Application for Prophylactic Treatment of HAE Using PHVS416
April 20, 2021
Pharvaris to Participate in BioCapital Europe
March 3, 2021
Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE
February 25, 2021
Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting
February 18, 2021
Pharvaris Announces Closing of Initial Public Offering
February 8, 2021
Pharvaris Announces Pricing of Upsized Initial Public Offering
February 3, 2021
Decks in 2021
- Technical Presentation (2021)
Technical · 9 slides · 2021